EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real‐World Safety of Vonoprazan in Patients and Symptom Outcomes in Patients With Reflux Esophagitis in China: A Prospective, Non‐Interventional Study ( VIEW )

Ying Lian Xiao, Hui Yang, Yi Xia Lu, Li Yang iD, Guo Xin Zhang, Guo Liang Ye, Qi Song, Li Xie iD, Min Hu Chen

Journal of Digestive Diseases · 2026-03 · 27 (3-4) · 150-159

DOI: 10.1111/1751-2980.70051 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Digestive Diseases, online erschienen am 21.05.2026. Verfasst von Ying Lian Xiao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China. Hauptthemen laut MEDLINE: Pyrroles, Sulfonamides, Esophagitis, Peptic, Proton Pump Inhibitors. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Vonoprazan was approved in China for reflux esophagitis (RE) in 2019; however, its real‐world safety and effectiveness remain undetermined. We aimed to evaluate the safety of vonoprazan in patients and its effectiveness in patients with RE in a real‐world setting.

Methods

In this prospective, non‐interventional, real‐world study, vonoprazan 20 mg was administered orally daily for 4 or 8 weeks. Primary endpoints were incidence rates of adverse events (AEs), serious AEs (SAEs), and adverse drug reactions (ADRs). Secondary endpoints included proportions of patients with RE without typical gastroesophageal reflux disease (GERD) symptoms (complete symptom relief) at baseline and Week 4, relief of heartburn/regurgitation symptoms (all day/nighttime) during Week 1, and mean change in GERD Questionnaire (GERDQ) score at Week 4.

Results

Of the 2829 patients with safety data, 488 (17.2%) reported ≥ 1 AE; 29 (1.0%) reported ≥ 1 SAE; and 129 (4.6%) reported ≥ 1 ADR. Of 1796 patients with RE and effectiveness data, the proportion without typical symptoms of GERD increased from 20.1% (95% confidence interval [CI] 18.29–22.05) at baseline to 55.2% (95% CI 52.63–57.79) at Week 4 (change: 35.1%, 95% CI 31.95–38.25). Complete relief from heartburn, nighttime heartburn, regurgitation, and nighttime regurgitation was observed in 32.3% (314/971), 43.8% (427/975), 27.0% (262/971), and 40.5% (395/976) patients, respectively, during Week 1. Mean change in GERDQ score ( n = 1464) improved by Week 4 (−1.70).

Conclusion

Vonoprazan is well tolerated through 8 weeks in patients and improves symptoms in patients with RE in the real‐world setting in China (VIEW; NCT04501627).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrrolesSulfonamidesEsophagitis, PepticProton Pump InhibitorsHumansFemaleProspective StudiesChinaMaleMiddle AgedTreatment OutcomeAdultAgedHeartburn

Stichwörter der Autor:innen

esophagitis, pepticgastroesophageal reflux diseasepotassium competitive acid blockersvonoprazan

Substanzen

PyrrolesSulfonamidesvonoprazanProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
  • Department of Gastroenterology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang Province, China.
  • Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, China.

ORCID-Profile: Li Yang, Li Xie

Förderung

  • Takeda Pharmaceutical Company Limited, China

Zitieren

APA

Xiao, Y. L., Yang, H., Lu, Y. X., Yang, L., Zhang, G. X., Ye, G. L., Song, Q., Xie, L., & Chen, M. H. (2026). Real‐World Safety of Vonoprazan in Patients and Symptom Outcomes in Patients With Reflux Esophagitis in China: A Prospective, Non‐Interventional Study ( VIEW ). Journal of Digestive Diseases, 27(3-4), 150-159. https://doi.org/10.1111/1751-2980.70051

Vancouver

Xiao YL, Yang H, Lu YX, Yang L, Zhang GX, Ye GL, et al. Real‐World Safety of Vonoprazan in Patients and Symptom Outcomes in Patients With Reflux Esophagitis in China: A Prospective, Non‐Interventional Study ( VIEW ). Journal of Digestive Diseases. 2026;27(3-4):150-159. doi:10.1111/1751-2980.70051

BibTeX
@article{Xiao2026,
  author = {Xiao, Ying Lian and Yang, Hui and Lu, Yi Xia and Yang, Li and Zhang, Guo Xin and Ye, Guo Liang and Song, Qi and Xie, Li and Chen, Min Hu},
  title = {Real‐World Safety of Vonoprazan in Patients and Symptom Outcomes in Patients With Reflux Esophagitis in China: A Prospective, Non‐Interventional Study ( VIEW )},
  journal = {Journal of Digestive Diseases},
  year = {2026},
  volume = {27},
  number = {3-4},
  pages = {150--159},
  doi = {10.1111/1751-2980.70051}
}
Kostenlos starten →